| Dr Wendy Ann Chamberlain, MD | |
|
5850 Ridge Rd, Parma, OH 44129-3169 | |
| (513) 834-7063 | |
| Not Available |
| Full Name | Dr Wendy Ann Chamberlain |
|---|---|
| Gender | Female |
| Speciality | Addiction Medicine |
| Experience | 19 Years |
| Location | 5850 Ridge Rd, Parma, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629236997 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 35.093119 (Ohio) | Secondary |
| 2083A0300X | Preventive Medicine - Addiction Medicine | 35.093119 (Ohio) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Brightview Llc | 9032426044 | 140 |
News Archive
A collaborative study between ContextVision AB, SharpView AB, Massachusetts General Hospital (MGH) and the Center for Medical Image Science and Visualization (CMIV) was announced today. The study will investigate advanced 3D image filtering as a means of increasing patient throughput and improving image quality in MRI and further enabling dose reduction in CT. Researchers will compare state-of-the-art 3D techniques with 2D filters.
The Children's Hospital of Philadelphia CEO Steven M. Altschuler, Drexel University President John A. Fry, and Hebrew University of Jerusalem President Menahem Ben-Sasson signed a research agreement on November 11 as part of Philadelphia Mayor Michael A. Nutter's trade mission to Israel. The research partnership is designed to focus on pediatric translational research and to develop a collaborative platform for advancing pediatric medicine from the lab to the bedside.
NeuroSigma, Inc., today announced conditional approval by the U.S. Food and Drug Administration of its Investigational Device Exemption application to commence a Phase III pivotal trial of the Monarch eTNS System for treatment of drug resistant epilepsy.
University of Texas at Austin researchers have demonstrated a new and more effective method for regrowing blood vessels in the heart and limbs - a research advancement that could have major implications for how we treat heart disease, the leading cause of death in the Western world.
› Verified 5 days ago
| Entity Name | Community Drug Board, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861566945 PECOS PAC ID: 8022061142 Enrollment ID: O20050301000178 |
News Archive
A collaborative study between ContextVision AB, SharpView AB, Massachusetts General Hospital (MGH) and the Center for Medical Image Science and Visualization (CMIV) was announced today. The study will investigate advanced 3D image filtering as a means of increasing patient throughput and improving image quality in MRI and further enabling dose reduction in CT. Researchers will compare state-of-the-art 3D techniques with 2D filters.
The Children's Hospital of Philadelphia CEO Steven M. Altschuler, Drexel University President John A. Fry, and Hebrew University of Jerusalem President Menahem Ben-Sasson signed a research agreement on November 11 as part of Philadelphia Mayor Michael A. Nutter's trade mission to Israel. The research partnership is designed to focus on pediatric translational research and to develop a collaborative platform for advancing pediatric medicine from the lab to the bedside.
NeuroSigma, Inc., today announced conditional approval by the U.S. Food and Drug Administration of its Investigational Device Exemption application to commence a Phase III pivotal trial of the Monarch eTNS System for treatment of drug resistant epilepsy.
University of Texas at Austin researchers have demonstrated a new and more effective method for regrowing blood vessels in the heart and limbs - a research advancement that could have major implications for how we treat heart disease, the leading cause of death in the Western world.
› Verified 5 days ago
| Entity Name | Brightview Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659769446 PECOS PAC ID: 9032426044 Enrollment ID: O20150923000820 |
News Archive
A collaborative study between ContextVision AB, SharpView AB, Massachusetts General Hospital (MGH) and the Center for Medical Image Science and Visualization (CMIV) was announced today. The study will investigate advanced 3D image filtering as a means of increasing patient throughput and improving image quality in MRI and further enabling dose reduction in CT. Researchers will compare state-of-the-art 3D techniques with 2D filters.
The Children's Hospital of Philadelphia CEO Steven M. Altschuler, Drexel University President John A. Fry, and Hebrew University of Jerusalem President Menahem Ben-Sasson signed a research agreement on November 11 as part of Philadelphia Mayor Michael A. Nutter's trade mission to Israel. The research partnership is designed to focus on pediatric translational research and to develop a collaborative platform for advancing pediatric medicine from the lab to the bedside.
NeuroSigma, Inc., today announced conditional approval by the U.S. Food and Drug Administration of its Investigational Device Exemption application to commence a Phase III pivotal trial of the Monarch eTNS System for treatment of drug resistant epilepsy.
University of Texas at Austin researchers have demonstrated a new and more effective method for regrowing blood vessels in the heart and limbs - a research advancement that could have major implications for how we treat heart disease, the leading cause of death in the Western world.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Wendy Ann Chamberlain, MD 615 Elsinore Pl Ste 200, Cincinnati, OH 45202-1457 Ph: (513) 834-7063 | Dr Wendy Ann Chamberlain, MD 5850 Ridge Rd, Parma, OH 44129-3169 Ph: (513) 834-7063 |
News Archive
A collaborative study between ContextVision AB, SharpView AB, Massachusetts General Hospital (MGH) and the Center for Medical Image Science and Visualization (CMIV) was announced today. The study will investigate advanced 3D image filtering as a means of increasing patient throughput and improving image quality in MRI and further enabling dose reduction in CT. Researchers will compare state-of-the-art 3D techniques with 2D filters.
The Children's Hospital of Philadelphia CEO Steven M. Altschuler, Drexel University President John A. Fry, and Hebrew University of Jerusalem President Menahem Ben-Sasson signed a research agreement on November 11 as part of Philadelphia Mayor Michael A. Nutter's trade mission to Israel. The research partnership is designed to focus on pediatric translational research and to develop a collaborative platform for advancing pediatric medicine from the lab to the bedside.
NeuroSigma, Inc., today announced conditional approval by the U.S. Food and Drug Administration of its Investigational Device Exemption application to commence a Phase III pivotal trial of the Monarch eTNS System for treatment of drug resistant epilepsy.
University of Texas at Austin researchers have demonstrated a new and more effective method for regrowing blood vessels in the heart and limbs - a research advancement that could have major implications for how we treat heart disease, the leading cause of death in the Western world.
› Verified 5 days ago
Dr. Jeffrey Christian Kirschman, M.D. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 12301 Snow Rd, Parma, OH 44130 Phone: 216-621-5600 Fax: 216-479-5554 |